Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Benefits"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
dewey-ones:"330 - Economics"
language:"English"
Showing
121
-
140
of
231
Search:
'"Benefits"'
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
121
Pharmacoeconomic review report: Certolizumab pegol (Cimzia) : (UCB Canada Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
122
Foot drop stimulators for foot drop : a review of clinical, cost-effectiveness, and guidelines
by
Ho, Chuong
,
Adcock, Lorna
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
123
Pharmacoeconomic review report: Tiotropium bromide monohydrate (Spiriva respimat) for inhalation
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
124
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
125
Pharmacoeconomic review report (resubmission): Nusinersen (Spinraza) (Biogen Canada Inc.) : indication : treatment of patients with 5q spinal muscular atrophy
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
126
Pharmacoeconomic review report (resubmission): Nusinersen (Spinraza) (Biogen Canada Inc.) : indication : treatment of patients with 5q spinal muscular atrophy
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
127
Rituximab maintenance therapy for the management of granulomatosis with polyangiitis or microscopic polyangiitis : a review of clinical effectiveness, cost-effectiveness, and guide...
by
Ho, Chuong
,
Adcock, Lorna
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
128
Rituximab for the treatment of myasthenia gravis : a review of clinical effectiveness, cost-effectiveness, and guidelines
by
Banerjee, Srabani
,
Adcock, Lorna
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
129
Sensory rooms for patients with dementia in long-term care : clinical and cost-effectiveness, and guidelines
by
Banerjee, Srabani
,
Ford, Caitlyn
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
130
Pharmacoeconomic review report: Levodopa/Carbidopa (Duodopa) (Abbvie Corporation) : indication : for the treatment of patients with advanced levodopa-responsive Parkinson's disease
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
131
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
132
CADTH Canadian Drug Expert Committee final recommendation: Selexipag (Uptravi -- Actelion Pharmaceuticals Canada Inc.) : Indication: pulmonary arterial hypertension
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
133
Pharmacoeconomic review report: Tiotropium bromide monohydrate (Spiriva respimat) for inhalation
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
134
CADTH Canadian Drug Expert Committee recommendation: Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) : indication : the treatment of adult and pediatric patients with hereditary ty...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
135
CADTH Canadian Drug Expert Committee recommendation: Glecaprevir / Pibrentasvir (Maviret -- Abbvie Corporation) : indication : chronic hepatitis C virus infection
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
136
CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
137
Pharmacoeconomic review report: Vortioxetine hydrobromide (Trintellix) (Lundbeck Canada Inc.) : indication : the treatment of major depressive disorder in adults
Published 2020
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
138
Guanfacine hydrochloride extended-release for the treatment of attention deficit hyperactivity disorder in adults : a review of clinical effectiveness, cost-effectiveness, and guid...
by
Poitras, Veronica
,
McCormack, Suzanne
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
139
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded i...
Published 2020
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
140
CADTH Canadian drug expert committee recommendation (final): Certolizumab pegol (Cimzia -- UCB Canada Inc.) : indication : treatment of adult patients with moderate-to severe plaqu...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
2
3
4
5
6
7
8
9
10
11
12
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Classification: 330 - Economics
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
330 - Economics
610 - Medicine & health
76
140 - Specific philosophical schools
19
700 - The arts; fine & decorative arts
17
580 - Plants (Botany)
3
600 - Technology
2
more ...
615 - Pharmacology & therapeutics
2
100 - Philosophy & psychology
1
363 - Other social problems & services
1
800 - Literature & rhetoric
1
see all ...
less ...
Language
English
Collection
National Center for Biotechnology Information
231
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
50
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
27
Adcock, Lorna
7
Ho, Chuong
7
Ford, Caitlyn
6
more ...
Grobelna, Aleksandra
5
Argáez, Charlene
4
Chao, Yi-Sheng
4
Gray, Casey
4
McCormack, Suzanne
4
Tran, Khai
4
Banerjee, Srabani
3
Campbell, Kaitryn
3
Loshak, Hannah
3
MacDougall, Danielle
3
Wells, Charlotte
3
Williams, D.
3
Young, Calvin
3
Farrah, Kelly
2
Frey, Nina
2
Jahagirdar, Deepa
2
Kanga, Ismat
2
Poitras, Veronica
2
Visintini, Sarah
2
Adams, Alison
1
Chiu, Stephanie
1
Cowling, Tara
1
De Nanassy, Alina
1
Edge, Rob
1
Harricharan, Sharada
1
Khangura, Sara
1
Klarenbach, Scott
1
Krahn, Murray
1
La Fleur, Philip
1
Lachance, Chantelle
1
Lee, Karen M.
1
Marchand, Dave K.
1
Membe, Stephen K.
1
Narain, Tasha
1
Palylyk-Colwell, Eugenia
1
Picheca, Lory
1
Singh, Sumeet
1
Spry, Carolyn
1
Thompson, Wade
1
Wong, William
1
Wright, Mary-Doug
1
Yeung, Shirley S. T.
1
see all ...
less ...
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?page=7&filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=dewey-ones%3A%22330+-+Economics%22&filter%5B%5D=language%3A%22English%22&lookfor=%22Benefits%22&type=Subject
Send by Email
×
Loading...